ERBB2 and neoplasm: There were no significant group differences in terms of age, BMI, tumor size, pathologic grade, clinical lymph node status, hormonal receptor status, HER‐2 positivity, Ki‐67 index, molecular subtype, NAC, or clinical disease stage.